Nan Yao

1.7k total citations · 1 hit paper
31 papers, 1.3k citations indexed

About

Nan Yao is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Nan Yao has authored 31 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 11 papers in Oncology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Nan Yao's work include MicroRNA in disease regulation (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Cancer Mechanisms and Therapy (4 papers). Nan Yao is often cited by papers focused on MicroRNA in disease regulation (4 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (4 papers) and Cancer Mechanisms and Therapy (4 papers). Nan Yao collaborates with scholars based in China, United States and Hong Kong. Nan Yao's co-authors include Wen‐Cai Ye, Dongmei Zhang, Zhe‐Sheng Chen, Yingjie Li, Chenran Wang, Nan Hu, Yuhe Lei, Minfeng Chen, Lijuan Deng and Wei‐Min Chen and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Hepatology.

In The Last Decade

Nan Yao

31 papers receiving 1.3k citations

Hit Papers

Autophagy and multidrug resistance in cancer 2017 2026 2020 2023 2017 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Autophagy and multidrug resistance in cancer
    2017 559 citations Yingjie Li, Yuhe Lei et al. Chinese Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nan Yao China 18 854 331 306 266 129 31 1.3k
Yuhe Lei China 15 795 0.9× 347 1.0× 332 1.1× 217 0.8× 111 0.9× 28 1.2k
Arumugam Nagalingam United States 21 875 1.0× 501 1.5× 431 1.4× 410 1.5× 117 0.9× 37 1.7k
Shuo Deng Singapore 11 786 0.9× 475 1.4× 273 0.9× 195 0.7× 103 0.8× 17 1.4k
Sonia Emanuele Italy 25 1.0k 1.2× 189 0.6× 321 1.0× 298 1.1× 104 0.8× 51 1.8k
Jianchun Wu China 18 753 0.9× 195 0.6× 206 0.7× 256 1.0× 174 1.3× 46 1.1k
Daniela Carlisi Italy 26 1.2k 1.4× 164 0.5× 508 1.7× 283 1.1× 96 0.7× 54 1.7k
Zhi Dai China 20 975 1.1× 653 2.0× 370 1.2× 241 0.9× 167 1.3× 59 1.9k
Guangjuan Zheng China 23 588 0.7× 164 0.5× 290 0.9× 255 1.0× 170 1.3× 59 1.3k

Countries citing papers authored by Nan Yao

Since Specialization
Citations

This map shows the geographic impact of Nan Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nan Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nan Yao more than expected).

Fields of papers citing papers by Nan Yao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nan Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nan Yao. The network helps show where Nan Yao may publish in the future.

Co-authorship network of co-authors of Nan Yao

This figure shows the co-authorship network connecting the top 25 collaborators of Nan Yao. A scholar is included among the top collaborators of Nan Yao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nan Yao. Nan Yao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yujing, Xue Zhao, Nan Yao, et al.. (2025). Formyl peptide receptor 1 and its antagonist T0080 in atherosclerosis. Cell Death and Differentiation. 32(10). 1859–1870. 1 indexed citations
2.
Yao, Nan, Bo Deng, Jinying Li, et al.. (2024). GINS1 promotes ZEB1‐mediated epithelial‐mesenchymal transition and tumor metastasis via β‐catenin signaling in hepatocellular carcinoma. Journal of Cellular Physiology. 239(5). e31237–e31237. 8 indexed citations
3.
Huang, Fei, Lihao Liu, Keke Zhang, et al.. (2024). Aurora B facilitates cholangiocarcinoma progression by stabilizing c‐Myc. SHILAP Revista de lepidopterología. 7(5). 626–640. 2 indexed citations
4.
Zhang, Di, Yang Xiao, Hui Yuan, et al.. (2023). Serine/threonine kinase TBK1 promotes cholangiocarcinoma progression via direct regulation of β-catenin. Oncogene. 42(18). 1492–1507. 10 indexed citations
5.
Zhang, Baohuan, Hui Yuan, Lihao Liu, et al.. (2023). A DNA/RNA heteroduplex oligonucleotide coupling asparagine depletion restricts FGFR2 fusion-driven intrahepatic cholangiocarcinoma. Molecular Therapy — Nucleic Acids. 34. 102047–102047. 1 indexed citations
6.
Hu, Shihe, Cuihua Jiang, Meng Gao, et al.. (2023). Discovery of pyrazolo[3,4-b]pyridine derivatives as novel and potent Mps1 inhibitors for the treatment of cancer. European Journal of Medicinal Chemistry. 253. 115334–115334. 8 indexed citations
7.
Tu, Mengxian, Lu He, Yang You, et al.. (2020). EFTUD2 maintains the survival of tumor cells and promotes hepatocellular carcinoma progression via the activation of STAT3. Cell Death and Disease. 11(10). 830–830. 20 indexed citations
8.
Yao, Nan, Chenran Wang, Mingqun Liu, et al.. (2020). Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. Signal Transduction and Targeted Therapy. 5(1). 214–214. 32 indexed citations
9.
Zhang, Jian, et al.. (2018). Three New Monoterpenoid Indole Alkaloids from Ervatamia pandacaqui. Chemistry & Biodiversity. 15(10). e1800268–e1800268. 6 indexed citations
10.
Deng, Lijuan, Ming Qi, Qi Qi, et al.. (2018). Arenobufagin induces MCF-7 cell apoptosis by promoting JNK-mediated multisite phosphorylation of Yes-associated protein. Cancer Cell International. 18(1). 209–209. 17 indexed citations
11.
Li, Yingjie, Yuhe Lei, Nan Yao, et al.. (2017). Autophagy and multidrug resistance in cancer. Chinese Journal of Cancer. 36(1). 52–52. 559 indexed citations breakdown →
12.
Chen, Liping, Minfeng Chen, Jianyang Hu, et al.. (2017). Arenobufagin inhibits prostate cancer epithelial-mesenchymal transition and metastasis by down-regulating β-catenin. Pharmacological Research. 123. 130–142. 59 indexed citations
13.
Li, Yingjie, Xiao‐Jun Huang, Nan Hu, et al.. (2017). Uncaria alkaloids reverse ABCB1-mediated cancer multidrug resistance. International Journal of Oncology. 51(1). 257–268. 24 indexed citations
14.
Sun, Haiyan, Maohua Huang, Nan Yao, et al.. (2017). The cycloartane triterpenoid ADCX impairs autophagic degradation through Akt overactivation and promotes apoptotic cell death in multidrug-resistant HepG2/ADM cells. Biochemical Pharmacology. 146. 87–100. 21 indexed citations
15.
Yao, Nan, Yingjie Li, Yuhe Lei, et al.. (2016). A piperazidine derivative of 23-hydroxy betulinic acid induces a mitochondria-derived ROS burst to trigger apoptotic cell death in hepatocellular carcinoma cells. Journal of Experimental & Clinical Cancer Research. 35(1). 192–192. 27 indexed citations
16.
Zhuo, Zhenjian, Jianyang Hu, Xiaolin Yang, et al.. (2015). Ailanthone Inhibits Huh7 Cancer Cell Growth via Cell Cycle Arrest and Apoptosis In Vitro and In Vivo. Scientific Reports. 5(1). 16185–16185. 87 indexed citations
17.
Yao, Nan, Yingjie Li, Dongmei Zhang, et al.. (2015). B4G2 Induces Mitochondrial Apoptosis by the ROS-Mediated Opening of Ca2+-Dependent Permeability Transition Pores. Cellular Physiology and Biochemistry. 37(3). 838–852. 18 indexed citations
18.
Li, Yingjie, Dong‐Hua Yang, Chenran Wang, et al.. (2015). Ganoderma lucidum derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells. International Journal of Oncology. 46(5). 2029–2038. 38 indexed citations
19.
Li, Yingjie, Nan Yao, Jun Xu, et al.. (2014). Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells. European Journal of Pharmacology. 733. 34–44. 20 indexed citations
20.
Cao, Huijuan, Ruirong Tan, Rong‐Rong He, et al.. (2012). Sarcandra glabraExtract Reduces the Susceptibility and Severity of Influenza in Restraint-Stressed Mice. Evidence-based Complementary and Alternative Medicine. 2012. 1–12. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuhe Lei Breakdown of academic impact, for papers by Arumugam Nagalingam Breakdown of academic impact, for papers by Shuo Deng Breakdown of academic impact, for papers by Sonia Emanuele Breakdown of academic impact, for papers by Jianchun Wu Breakdown of academic impact, for papers by Daniela Carlisi Breakdown of academic impact, for papers by Zhi Dai Breakdown of academic impact, for papers by Guangjuan Zheng
Rankless by CCL
2026